Combined with mutagenesis and functional experiments, we aim to leverage these structural insights to guide the development of antibody therapeutics targeting GPRC5D, addressing the current gap in the treatment of multiple myeloma. This evidence concerns the gene GPRC5D and AL amyloidosis.